HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Enoximone

A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.

Also Known As:

Aventis Brand of Enoximone; Carinopharm Brand of Enoximone; Fenoximone; MDL 19438; MDL-17,043; MDL-17043; MDL-19,438; Myogen Brand of Enoximone; Perfan; Enoximone Aventis Brand; Enoximone Carinopharm Brand; Enoximone Myogen Brand; MDL 17,043; MDL 17043; MDL 19,438; MDL17,043; MDL17043; MDL19,438; 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-

Networked: 271 relevant articles (47 outcomes, 54 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Azoles: 413
    - Imidazoles: 107
      - Enoximone: 271
        enoximone sulfoxide: 2

Experts

1.	Bristow, Michael R: 5 articles (11/2010 - 10/2002)
2.	Metra, Marco: 4 articles (12/2009 - 10/2002)
3.	Eichhorn, Eric: 3 articles (12/2009 - 12/2005)
4.	Robertson, Alastair D: 3 articles (11/2007 - 10/2002)
5.	Boldt, Joachim: 3 articles (09/2007 - 10/2002)
6.	Fiege, M: 3 articles (04/2005 - 03/2000)
7.	Weisshorn, R: 3 articles (04/2005 - 03/2000)
8.	Wappler, F: 3 articles (04/2005 - 03/2000)
9.	Comito, Cosimo: 2 articles (09/2013 - 09/2003)
10.	Gilbert, Edward M: 2 articles (11/2010 - 11/2007)

Related Diseases

1.	Heart Failure 01/01/1994 - "A marked dose-dependent improvement in left ventricular pump performance was observed, with only minor changes in heart rate or systemic blood pressure, if enoximone was administered as i.v. -bolus to patients with moderate to severe congestive heart failure. " 07/22/1991 - "Enoximone, a phosphodiesterase-inhibitor, is a potent inotropic vasodilator agent that causes a marked improvement in hemodynamics in patients with congestive heart failure. " 08/14/1987 - "Enoximone, a phosphodiesterase inhibitor, is a potent inotropic vasodilator agent that causes a marked improvement in systemic hemodynamics in patients with severe chronic congestive heart failure. " 05/01/1991 - "Heart failure symptoms and the physicians' evaluations of cardiac status were significantly improved in both enoximone therapy groups during the first 4 weeks of evaluation when compared with evaluations of cardiac status in the placebo group. " 01/01/1989 - "Thus, long-term enoximone therapy is safe and produces sustained clinical and functional improvement in unstable chronic heart failure. "
2.	Cardiogenic Shock 01/01/1992 - "Enoximone thus improved hemodynamic performance significantly in cardiogenic shock after open-heart surgery. " 03/01/1994 - "Enoximone proved to be safe and effective in the treatment of cardiogenic shock. " 01/01/1992 - "Efficacy of phosphodiesterase inhibitor enoximone in management of postcardiotomy cardiogenic shock." 07/01/1990 - "In one study of 13 patients in cardiogenic shock already receiving adrenergic support, enoximone was administered as a bolus of 0.5 mg/kg over 20 minutes. " 09/01/2013 - "At multivariable analysis age (OR2.75, p=0.0004), diabetes (OR1.82, p=0.006), preoperative GFR (OR3.81, p<0.0001), preoperative cardiogenic shock (OR1.65, p=0.004), previous cardiac surgery (OR2.12, p=0.0002), type of intervention (OR1.96, p=0.005), and enoximone (OR0.38, p=0.001) were found to be independently associated with postoperative RF. "
3.	Stroke (Strokes) 11/01/1984 - "Following MDL 17,043, there was an increase in cardiac index (+62%), stroke volume index (+42%), and stroke work index (+68%), together with a decrease in pulmonary capillary wedge pressure (-46%), indicating improved left ventricular pump function. " 08/01/1996 - "Compared to the baseline the maximum effects of enoximone were a 28% increase of cardiac index accompanied by a 39% decline of systemic vascular resistance and an unchanged left-ventricular stroke-work index. " 01/01/1994 - "Addition of enoximone (bolus dose 1.0 mg.kg-1 followed by continuous infusion of 7 micrograms.kg-1.min-1) induced an increase of CI to 3.6 +/- 1.3 L.min-1.m-2 (p < 0.05) and of left ventricular stroke work index (LVSWI) from 21.8 +/- 3.6 g.m.m-2 to 29.3 +/- 10.1 g.m.m-2 (p < 0.05). " 01/01/1989 - "Furthermore, when left ventricular stroke work index was plotted as a function of the left ventricular enddiastolic pressure, enoximone shifted the left ventricular function curve to the left. " 11/01/1984 - "Stroke volume index and stroke work index increased, and right atrial and pulmonary arterial pressures and systemic vascular resistance decreased by similar magnitude after both intravenous and oral MDL 17043 (all p less than 0.001). "
4.	Pulmonary Hypertension (Ayerza Syndrome) 05/01/1999 - "High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements?" 04/01/1993 - "This endothelium-independent vasodilatory effect of enoximone makes it a potentially valuable drug for the treatment of pulmonary hypertension. " 03/01/1992 - "Enoximone should not be administered in pulmonary hypertension, as suggested before." 04/01/1995 - "Treatment of pulmonary hypertension in the weaning and early post-bypass period consisted of respiratory (PaCO2 < 30 mmHg) and metabolic alkalinisation (pH 7.45-7.55, BE > +3 mmol/l), the use of prostaglandin E1 (3-6-12 micrograms/kg.h), and the phosphodiesterase inhibitor enoximone (10-15 micrograms/kg.min). " 01/01/1989 - "With regard to persistent pulmonary hypertension in newborns, enoximone was also used in piglets to investigate the effects on endotoxin-induced, dopamine-resistant pulmonary hypertension. "
5.	Low Cardiac Output 06/01/1997 - "[Enoximone in the treatment of postoperative low cardiac output syndrome in pediatric heart surgery. " 12/01/1995 - "In turn, the PDE III-inhibitor enoximone has been used for several years to treat low cardiac output syndrome. " 03/01/1991 - "We conclude that enoximone, single or in association with other inotropics, should be considered a drug of choice in patients undergoing cardiac surgery who develop a low cardiac output syndrome." 11/01/1990 - "Low cardiac output and enoximone." 05/01/1990 - "Management of low cardiac output syndrome after cardiac surgery using enoximone."

Related Drugs and Biologics

1.	Dobutamine
2.	Vasodilator Agents (Vasodilators)
3.	Enoximone
4.	Nitroprusside (Sodium Nitroprusside)
5.	Nitroglycerin (Dynamite)
6.	simendan (Levosimendan)
7.	Diuretics
8.	esmolol (Brevibloc)
9.	Catecholamines
10.	Metoprolol (Lopressor)

Related Therapies and Procedures

1.	Heart Transplantation (Grafting, Heart)
2.	Cardiopulmonary Bypass (Heart-Lung Bypass)
3.	Transplantation (Transplant Recipients)
4.	Counterpulsation (External Counterpulsation)
5.	Oral Administration